Credit Suisse Group assumed coverage on shares of Genesis Healthcare (NYSE:GEN) in a research note published on Tuesday morning, The Fly reports. The brokerage issued a neutral rating and a $1.75 target price on the stock.

Several other analysts have also recently issued reports on the company. ValuEngine cut Genesis Healthcare from a buy rating to a hold rating in a research note on Wednesday, July 18th. Cantor Fitzgerald reissued a buy rating and issued a $7.00 target price on shares of Genesis Healthcare in a research note on Tuesday, August 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $3.19.

Shares of NYSE:GEN opened at $1.53 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of -2.61. The stock has a market cap of $218.07 million, a PE ratio of -0.73 and a beta of 0.79. Genesis Healthcare has a 12-month low of $0.60 and a 12-month high of $2.86.

Genesis Healthcare (NYSE:GEN) last posted its earnings results on Tuesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.13). The company had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the previous year, the firm earned ($0.70) earnings per share. As a group, analysts anticipate that Genesis Healthcare will post -1.42 EPS for the current year.

In related news, Director David A. Reis sold 47,755 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $1.74, for a total value of $83,093.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 380,135 shares of company stock worth $647,593 over the last three months. 58.10% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new stake in Genesis Healthcare in the second quarter worth about $120,000. Schwab Charles Investment Management Inc. purchased a new stake in Genesis Healthcare in the first quarter worth about $153,000. California Public Employees Retirement System lifted its holdings in Genesis Healthcare by 23.3% in the first quarter. California Public Employees Retirement System now owns 309,910 shares of the company’s stock worth $468,000 after buying an additional 58,610 shares during the period. Millennium Management LLC lifted its holdings in Genesis Healthcare by 40.6% in the first quarter. Millennium Management LLC now owns 338,678 shares of the company’s stock worth $511,000 after buying an additional 97,834 shares during the period. Finally, Macquarie Group Ltd. lifted its holdings in Genesis Healthcare by 27.2% in the second quarter. Macquarie Group Ltd. now owns 314,967 shares of the company’s stock worth $721,000 after buying an additional 67,300 shares during the period. 19.72% of the stock is currently owned by institutional investors.

Genesis Healthcare Company Profile

Genesis Healthcare, Inc, together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy.

See Also: Hedge Funds – Risk or Reward?

The Fly

Receive News & Ratings for Genesis Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genesis Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.